Tags

Type your tag names separated by a space and hit enter

[Homocysteine, folic acid, group B vitamins and cardiovascular risk].
Arch Mal Coeur Vaiss. 2005 Feb; 98(2):145-52.AM

Abstract

Although there is a high degree of proof relating plasma homocysteine levels to cardiovascular risk, the role of homocysteine as a causal cardiovascular risk factor remains controversial. Prospective long-term clinical trials in high cardiovascular risk populations usually show a positive relationship between plasma homocysteine and the degree of cardiovascular risk. However, shorter term studies and/or those carried out in populations with lower cardiovascular risk show either a weaker correlation or no relationship at all. To date no study has shown proof of the reversibility of cardiovascular risk due to hyperhomocysteinaemia; nevertheless, a number of studies using intermediate criteria support the hypothesis of a benefit due to reduction of plasma homocysteine levels. A number of therapeutic trials published with clinical criteria have not shown convincing results in either direction. A number of interventional trials are underway: notably the SUFOLOM 3 trial in France, and the question of a benefit on cardiovascular risk by reducing homocysteine levels should be answered in the next few years. In the meantime, with the exception of homocysteinuria in which therapeutic strategies have shown their efficacy in the reduction of atherothrombotic risk with high levels of proof, the authors do not recommend the treatment of mild hyperhomocysteinaemia in any clinical setting other than "clinical trials" and certain "compassionate" indications such as early and/or recurrent vascular events associated with hyperhomocysteinaemia in the absence of conventional risk factors.

Authors+Show Affiliations

Centre de Diagnostic, Unité Hypertension Artérielle, Soins et Prévention Cardiovasculaires. jacques.blacher@htd.ap-hop-paris.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

15787307

Citation

Blacher, J, et al. "[Homocysteine, Folic Acid, Group B Vitamins and Cardiovascular Risk]." Archives Des Maladies Du Coeur Et Des Vaisseaux, vol. 98, no. 2, 2005, pp. 145-52.
Blacher J, Czernichow S, Horrellou MH, et al. [Homocysteine, folic acid, group B vitamins and cardiovascular risk]. Arch Mal Coeur Vaiss. 2005;98(2):145-52.
Blacher, J., Czernichow, S., Horrellou, M. H., Conad, J., David, P., Chadefaux-Vekemans, B., Ankria, A., Galan, P., Hercberg, S., & Ducimetière, P. (2005). [Homocysteine, folic acid, group B vitamins and cardiovascular risk]. Archives Des Maladies Du Coeur Et Des Vaisseaux, 98(2), 145-52.
Blacher J, et al. [Homocysteine, Folic Acid, Group B Vitamins and Cardiovascular Risk]. Arch Mal Coeur Vaiss. 2005;98(2):145-52. PubMed PMID: 15787307.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Homocysteine, folic acid, group B vitamins and cardiovascular risk]. AU - Blacher,J, AU - Czernichow,S, AU - Horrellou,M H, AU - Conad,J, AU - David,P, AU - Chadefaux-Vekemans,B, AU - Ankria,A, AU - Galan,P, AU - Hercberg,S, AU - Ducimetière,P, PY - 2005/3/25/pubmed PY - 2005/5/18/medline PY - 2005/3/25/entrez SP - 145 EP - 52 JF - Archives des maladies du coeur et des vaisseaux JO - Arch Mal Coeur Vaiss VL - 98 IS - 2 N2 - Although there is a high degree of proof relating plasma homocysteine levels to cardiovascular risk, the role of homocysteine as a causal cardiovascular risk factor remains controversial. Prospective long-term clinical trials in high cardiovascular risk populations usually show a positive relationship between plasma homocysteine and the degree of cardiovascular risk. However, shorter term studies and/or those carried out in populations with lower cardiovascular risk show either a weaker correlation or no relationship at all. To date no study has shown proof of the reversibility of cardiovascular risk due to hyperhomocysteinaemia; nevertheless, a number of studies using intermediate criteria support the hypothesis of a benefit due to reduction of plasma homocysteine levels. A number of therapeutic trials published with clinical criteria have not shown convincing results in either direction. A number of interventional trials are underway: notably the SUFOLOM 3 trial in France, and the question of a benefit on cardiovascular risk by reducing homocysteine levels should be answered in the next few years. In the meantime, with the exception of homocysteinuria in which therapeutic strategies have shown their efficacy in the reduction of atherothrombotic risk with high levels of proof, the authors do not recommend the treatment of mild hyperhomocysteinaemia in any clinical setting other than "clinical trials" and certain "compassionate" indications such as early and/or recurrent vascular events associated with hyperhomocysteinaemia in the absence of conventional risk factors. SN - 0003-9683 UR - https://www.unboundmedicine.com/medline/citation/15787307/[Homocysteine_folic_acid_group_B_vitamins_and_cardiovascular_risk]_ DB - PRIME DP - Unbound Medicine ER -